The Serum Institute of India (SII) and Oxford University have launched a "high efficacy" malaria vaccine, R21/Matrix-M, in Cote d'Ivoire. Approved by the WHO, the vaccine is effective, affordable, and can be mass-produced quickly. SII aims to produce 100 million doses annually, pricing each at under USD 4. Initially, 656,600 doses will vaccinate 250,000 children in Cote d'Ivoire. The vaccine is also authorized in Ghana, Nigeria, Burkina Faso, and the Central African Republic. It promises significant progress in combating malaria in Africa, potentially saving thousands of lives.
